SHAREHOLDER ALERT: Robbins LLP Informs Investors of Class Action Against Cabaletta Bio, Inc. (CABA)
SAN DIEGO--(BUSINESS WIRE)--$CABA #attorney--The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or acquired Cabaletta Bio, Inc. (NASDAQ: CABA) (1) common stock pursuant to the Company's October 2019 IPO or (2) securities between October 24, 2019 and December 13, 2021. Cabaletta Bio is a clinical-stage biotechnology company that discovers and develops engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial.
If you would like more information about our investigation of Cabaletta Bio, Inc.'s misconduct, click here.
What is this Case About: Cabaletta Bio, Inc. (CABA) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
According to the complaint, the documents in support of the IPO were negligently prepared and defendants made misleading statements during the class period. Specifically, the offering documents and defendants' subsequent statements failed to disclose that top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion. Because DSG3-CAART was not as effective as represented to investors, the Company had overstated DSG3-CAART's clinical and/or commercial prospects.
On December 24, 2021, Cabaletta reported "top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV)." Among other results, Cabaletta reported that two cohort participants had "disease activity scores that worsened … after DSG3-CAART infusion" and thus "reduced or discontinued selected systemic therapies prior to DSG3-CAART infusion, as required by the protocol," while another participant "subsequently received systematic medication to improve disease activity after DSG3-CAART infusion." On this news, Cabaletta's stock fell $9.15 per share, or over 73% to close at $3.36 per share on December 14, 2021. The stock continues to trade well below the $11.00 IPO price.
Next Steps: If you acquired shares of Cabaletta Bio, Inc. (CABA) pursuant to its IPO or between October 24, 2019 and December 13, 2021, you have until April 29, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Cabaletta Bio, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
5040 Shoreham Place
San Diego, CA 92122